- Home
- AMRX
as 06-20-2025 4:00pm EST
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 2.3B | IPO Year: | N/A |
| Target Price: | $11.50 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.29 - $9.47 | Next Earning Date: | 08-08-2025 |
| Revenue: | $2,830,186,000 | Revenue Growth: | 13.42% |
| Revenue Growth (this year): | 9.84% | Revenue Growth (next year): | 7.33% |
Stock Insider Trading Activity of Amneal Pharmaceuticals Inc. (AMRX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Patel Gautam | AMRX | Director | Jun 10 '25 | Sell | $8.02 | 56,426 | $452,536.52 | 1,704,050 | |
| Shah Nikita | AMRX | Executive Vice President | May 16 '25 | Sell | $7.58 | 49,140 | $372,481.20 | 388,929 | |
| Kiely John | AMRX | Director | May 12 '25 | Sell | $7.59 | 50,000 | $379,500.00 | 257,433 | |
| Patel Gautam | AMRX | Director | May 2 '25 | Sell | $8.00 | 8,668 | $69,344.00 | 1,704,050 | |
| Patel Gautam | AMRX | Director | Apr 1 '25 | Sell | $8.30 | 80,000 | $664,000.00 | 1,704,050 |
Latest Amneal Pharmaceuticals Inc. News
AMRX Breaking Stock News: Dive into AMRX Ticker-Specific Updates for Smart Investing
The Wall Street Journal
4 days ago
Generic Drugmakers Resist Trump’s Calls for More U.S. Manufacturing
GlobeNewswire
9 days ago
Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension
GlobeNewswire
23 days ago
Amneal to Participate at Upcoming Investor Conferences in June
GlobeNewswire
a month ago
Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults
GlobeNewswire
a month ago
Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S.
GuruFocus.com
2 months ago
Amneal Pharmaceuticals Inc (AMRX) Q1 2025 Earnings Call Highlights: Strong Growth and Strategic ...
Business Wire
2 months ago
Amneal Reports First Quarter 2025 Financial Results
GuruFocus.com
2 months ago
Amneal Pharmaceuticals Inc (AMRX) Q1 2025 Earnings Report Preview: What To Expect
Compare AMRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AMRX Amneal Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.